Previous 10 | Next 10 |
Argus Research has started Enovis Corp. (NYSE:ENOV) with a hold rating as it has concerns about EPS growth and "steep competition" from medical device peers. The firm does not have a price target. Analyst John Eade said that Enovis' record on EPS growth is not as strong as rivals, adding that...
A comprehensive ankle plating portfolio, designed with the proven technology of Arsenal Foot Plating System, expands offerings to address both tri-malleolar and intra-articular fracture patterns DJO® is now part of the Enovis™ family.* Enovis Corporation, an inno...
Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Amid a rocky market quarter overall, Diamond Hill Mid Cap Fund's negative returns still outpaced the Ru...
Wilmington, DE, June 06, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference on Monday, June 13, 202...
Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Amid a rocky market quarter overall, our portfolio’s negative returns still outpaced the Russell...
Enovis has been the medtech segment which remained following the spin-off from Colfax. The standalone business has some to prove, as margins need a boost to create appeal here. I think that the valuations here are too demanding, preferring the welding ESAB business. For furt...
ESAB is the welding business which has been spun off from its former parent, called Colfax. After cutting the 2022 guidance, I still find confidence in a solid strategy even after 2022 is set to be a rockier year, while spin-offs face inherent uncertainty. Amidst non-demanding val...
The following slide deck was published by Enovis Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Enovis Corporation 2022 Q1 - Results - Earnings Call Presentation
Enovis Corporation (ENOV) Q1 2022 Earnings Conference Call May 10, 2022 08:00 AM ET Company Participants Christopher Hix - Executive Vice President & Chief Financial Officer Matthew Trerotola - Chief Executive Officer Conference Call Participants Jeff Johnson - Robert W. Baird & Co. M...
Enovis Corporation press release (NYSE:ENOV): Q1 GAAP EPS of $0.33. Revenue of $1.02B (+16.0% Y/Y). For further details see: Enovis Corporation GAAP EPS of $0.33, revenue of $1.02B
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 15:15:06 ET Needham analyst issues BUY recommendation for ENOV on July 2, 2024 01:01PM ET. The previous analyst recommendation was Buy. ENOV was trading at $44.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
2024-07-02 09:00:08 ET Vijay Kumar from Evercore ISI issued a price target of $62.00 for ENOV on 2024-07-02 08:02:00. The adjusted price target was set to $62.00. At the time of the announcement, ENOV was trading at $44.35. The overall price target consensus is at $67.00...
Wilmington, DE, May 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Bank of America Healthcare Conference: Ben ...